Achondroplasia — the most common skeletal dysplasia and now the first with a targeted growth-modifying therapy (vosoritide), where molecular confirmation of the FGFR3 variant is required for treatment eligibility.
Whole genome sequencing confirms the specific FGFR3 variant — distinguishing achondroplasia from hypochondroplasia, thanatophoric dysplasia, and other FGFR3-related skeletal conditions that present with overlapping features but require different management.
Achondroplasia
Achondroplasia is the most common form of disproportionate short stature, affecting approximately 1 in 15,000-40,000 births worldwide. It is caused by a specific gain-of-function missense variant in FGFR3 (fibroblast growth factor receptor 3) on chromosome 4p16.3 — p.Gly380Arg (c.1138G>A, accounting for ~98% of cases, or c.1138G>C, accounting for ~1-2%). FGFR3 is a negative regulator of endochondral ossification: the gain-of-function variant constitutively activates the receptor, suppressing chondrocyte proliferation and differentiation at the growth plate, producing rhizomelic (proximal) limb shortening.
Achondroplasia is autosomal dominant with complete penetrance. Approximately 80% of cases arise as de novo mutations — both parents are of average stature. Advanced paternal age is a risk factor for de novo FGFR3 variants. Clinical features include rhizomelic short limbs, macrocephaly with frontal bossing, midface hypoplasia, trident hand configuration, and lumbar lordosis. Medical complications include foramen magnum stenosis (requiring neurosurgical assessment in infancy), obstructive sleep apnea, recurrent otitis media, and spinal stenosis in adulthood. Adult height averages approximately 131cm in males and 124cm in females.
Vosoritide (Voxzogo), a C-type natriuretic peptide analog that counteracts FGFR3-mediated growth plate suppression, was approved by the FDA in 2021 and the EMA in 2021 for treatment of achondroplasia in children aged 5 and older with open growth plates. Clinical trials demonstrated a mean increase in annualized growth velocity of approximately 1.57 cm/year compared to placebo. Vosoritide is the first targeted, disease-modifying therapy for any skeletal dysplasia — and molecular confirmation of the FGFR3 achondroplasia variant is required for prescribing eligibility.
Homozygous achondroplasia (both FGFR3 alleles carrying p.Gly380Arg) is a lethal condition with severe skeletal abnormalities and respiratory failure. Couples where both partners have achondroplasia have a 25% risk of a homozygous-affected pregnancy — genetic counseling is essential.
Clinical diagnosis of achondroplasia is usually straightforward, but molecular confirmation is required for vosoritide eligibility and distinguishes achondroplasia from other FGFR3 skeletal dysplasias with different prognoses.
Vosoritide prescribing requires confirmed FGFR3 achondroplasia variant — clinical diagnosis alone is not sufficient
Vosoritide (Voxzogo) is indicated specifically for achondroplasia confirmed by FGFR3 molecular testing. Other FGFR3-related skeletal dysplasias — hypochondroplasia (FGFR3 p.Asn540Lys), thanatophoric dysplasia types I and II (various FGFR3 variants), and SADDAN (Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans) — are caused by different FGFR3 variants with different functional consequences. Vosoritide clinical trial data specifically applies to the achondroplasia p.Gly380Arg variant. Molecular confirmation ensures that the therapy is being applied to the correct genotype and that clinical trial efficacy data is applicable.
Couples where both partners have achondroplasia face a 25% risk of lethal homozygous disease — genetic counseling requires confirmed genotype
When both parents have achondroplasia, each pregnancy has a 25% chance of homozygous achondroplasia (lethal), 50% chance of heterozygous achondroplasia (like the parents), and 25% chance of average stature. Prenatal molecular diagnosis through CVS or amniocentesis can distinguish these outcomes, and PGT-M with IVF can select against the homozygous genotype. This reproductive counseling requires confirmed FGFR3 variant characterization in both parents. Additionally, some patients clinically diagnosed with achondroplasia may actually have hypochondroplasia or another skeletal dysplasia — molecular confirmation resolves diagnostic ambiguity.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Achondroplasia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
